Document Detail


Very late thrombosis of paclitaxel-eluting stent.
MedLine Citation:
PMID:  18928954     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Drug-eluting stents (DES) have been proven to be effective in reducing restenosis after percutaneous coronary interventions, but they are associated with a risk of late thrombotic occlusion with adverse clinical events. We report a case of an angiographically confirmed paclitaxel-eluting stent (PES) thrombosis which occurred 36 months after successful stent implantation. To the best of our knowledge, this is the most delayed case of PES thrombosis described so far.
Authors:
Vedat Aytekin; Refik Erdim; Selcuk Gormez; Cemsid Demiroglu
Related Documents :
8961914 - Preliminary experience with low-dose methotrexate in fibroblastic rheumatism.
7080054 - Envenomation by the northern blacktail rattlesnake (crotalus molossus molossus): report...
15300114 - Deepening of lid sulcus from topical bimatoprost therapy.
1685234 - Electroconvulsive therapy for mania.
19886044 - Primary adenocarcinoma of the appendix: an update.
2250894 - True posterior ischemic optic neuropathy associated with herpes zoster ophthalmicus.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Cardiovascular revascularization medicine : including molecular interventions     Volume:  9     ISSN:  1878-0938     ISO Abbreviation:  -     Publication Date:    2008 Oct-Dec
Date Detail:
Created Date:  2008-10-20     Completed Date:  2009-02-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101238551     Medline TA:  Cardiovasc Revasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  275-7     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Florence Nightingale Hospital, Istanbul Science University, Istanbul, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary / adverse effects*,  instrumentation
Cardiovascular Agents / administration & dosage*
Coronary Angiography
Coronary Stenosis / therapy*
Coronary Thrombosis / etiology*,  prevention & control,  radiography
Drug-Eluting Stents*
Humans
Male
Middle Aged
Paclitaxel / administration & dosage*
Platelet Aggregation Inhibitors / therapeutic use
Time Factors
Chemical
Reg. No./Substance:
0/Cardiovascular Agents; 0/Platelet Aggregation Inhibitors; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Percutaneous Impella Recover circulatory support in high-risk coronary angioplasty.
Next Document:  Intracoronary guidewire emboli: a unique complication and retrieval of the wire.